Showing posts with label PHARMA UPDATES. Show all posts
Showing posts with label PHARMA UPDATES. Show all posts

Tuesday, 7 November 2017

LUPIN GETS WARNING LETTER FROM USFDA FOR GOA, INDORE UNITS



The company had earlier received three form 483 observations for the Goa facility on April 7, 2017 and six form 483 observations for Pithampur (Unit II) on May 19, 2017, Lupin said, adding that it had responded to all the observations.
New Delhi: Drug firm Lupin today said it has received warning letter from the US health regulator for its manufacturing facilities in Goa and Pithampur, Indore.
The company had earlier received three form 483 observations for the Goa facility on April 7, 2017 and six form 483 observations for Pithampur (Unit II) on May 19, 2017, Lupin said, adding that it had responded to all the observations.
"The company has received a warning letter issued by the United States Food and Drug Administration (USFDA) on November 6, 2017 for our formulation manufacturing facilities at Goa and Indore (Pithampur Unit II)", Lupin said in a filing to BSE.
The company is deeply disappointed to have received this outcome, it said, adding that while there will be no disruption of product supplies from either of these locations, there is likely be a delay of new product approvals.
Lupin however did not share the concerns raised by the US health regulator in its warning letter.
"We plan to address the concerns raised by the USFDA expeditiously and will work with the USFDA to resolve these issues at the earliest," Lupin said.
The company upholds quality and compliance issues with utmost seriousness and remains fully committed to be compliant with cGMP quality standards across all the facilities, it added.
Lupin Ltd stock crashed over 17 per cent to about Rs 856 on BSE in the afternoon.
For more updates follow srinivasulutirumalasetty.blogspot.com

Thank you for visiting my blog , Visit again for latest pharma updates
Posted by at No comments:
Labels:

Wednesday, 12 April 2017

DIFFERENT FORMS ISSUED BY @@ USFDA


Guys working in FDA approved industry's has to know the following...

 There are different forms those are issued by the FDA at the different stages of the regulatory audits. Different issues are communicated through these forms between FDA and the manufacturing facility. Some of them are:

 1. FDA Form 482 - Notice of Inspection

 2. FDA Form 483 - Observations of Inspection

 3. FDA Form 484 - Receipt of Samples

 4. FDA Form 463 - Affidavit

 1. FDA Form 482 - Notice of Inspection:

 It is an official notice of FDA for inspection signed by the FDA officials. It is produced by the inspector and has the authority to inspect the manufacturing facility. Inspection coordinator will receive the notice and manage the inspection accordingly. Coordinator should ask for notice, if it is not presented by the FDA inspector. A copy of this notice shall be attached with the inspection file.

 Form 482 shows that inspector has authorization from FDA to inspect the facility. It clearly shows what the inspector may inspect including the area of inspection and documentation.

 An inspector can ask for the manufacturing records of the regulated product and can enter in the area where the product is being manufactured. He can review online records, collect samples and interview the personnel working in area.

 An inspector can’t review the product price list, financial data of firm, product marketing data, research documents and employee data excluding the training records. These documents are considered as firm’s confidential documents.

 2. FDA Form 483 - Observations of Inspection:

 Inspector shall provide the list of his observations about inspection on Form 483. It has all points noticed by the FDA inspectors. An observation made in previous inspection that is not corrected can be added in 483. The original copy of the FDA Form 483 is presented to the firm’s management, generally to the person who had received the Notice of Inspection.

 3. FDA Form 484 - Receipt of Samples:

 During the inspection if FDA inspectors want to take any sample, they have to issue a receipt of those samples on Form 484. it has quantity of sample with the lot number of the product sampled. Form 484 is used for samples only but not for promotional material, labels, photographs or any record taken by FDA investigators.

 4. FDA Form 463 - Affidavit:

 An affidavit is produced by the production authorities declaring the receipt and use of the raw material used in product manufacturing after the completion of the FDA audit.
For more updates follow srinivasulutirumalasetty.blogspot.com


Thank you for visiting my blog , Visit again for latest pharma updates
Posted by at No comments:
Labels:

Tuesday, 4 April 2017

HRD ANNOUNCED RANKINGS OF TOP PHARMACY COLLEGES IN ALL OVER INDIA

Delhi’s Jamia Hamdard is the best place to study pharmacy in India, closely followed by the National Institute of Pharmaceutical Education and Research in Mohali, said a government ranking on Monday.

The India Rankings 2017, released by human resource development minister Prakash Javadekar, put Chandigarh’s University Institute of Pharmaceutical Sciences at number 3, Institute of Chemical Technology in Mumbai at 4 and National Institute of Pharmaceutical Education and Research, Hyderabad, at 5.


Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)